NCT03807765: Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases

NCT03807765
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Radiation Therapy, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have 10 or less brain metastases eligible for SRS
Exclusions: Patients with presence of leptomeningeal disease; Prior whole brain radiation therapy
https://ClinicalTrials.gov/show/NCT03807765

Comments are closed.

Up ↑